Next generation of immune checkpoint inhibitors and beyond

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy

(2020) Adam S. Dayoub et al.   Cell Communication and Signaling

Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

(2020) M. Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Biology and therapeutic targeting of tumour‐associated macrophages

(2020) Tim Beltraminelli et al.   JOURNAL OF PATHOLOGY

Importance of semaphorins in cancer immunity

(2020) Li-Han Chen et al.   Translational Lung Cancer Research

CCL2/CCR2 signaling in cancer pathogenesis

(2020) Qiongyu Hao et al.   Cell Communication and Signaling

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

(2020) Roger B. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.

(2020) Laura Quan Man Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.

(2020) John D. Powderly et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.

(2020) Roni Shapira et al.   JOURNAL OF CLINICAL ONCOLOGY

Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.

(2020) Thorsten Oliver Goetze et al.   JOURNAL OF CLINICAL ONCOLOGY

Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.

(2020) Krish Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.

(2020) Michael Rahman Shafique et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.

(2020) Melissa Lynne Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of clinical activity of NEO201 mAb with the expression of NK activation markers and levels of soluble factors.

(2020) M. Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

(2020) Enriqueta Felip et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.

(2020) Petri Bono et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

(2020) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).

(2020) Corey Carter et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-8 and cancer prognosis on immunotherapy

(2020) Ziad Bakouny et al.   NATURE MEDICINE

CD47: the next checkpoint target for cancer immunotherapy

(2020) Ridong Feng et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

(2020) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function

(2019) Sarah Whelan et al.   Cancer Immunology Research

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

(2019) Benjamin C. Creelan et al.   Nature Reviews Clinical Oncology

Adding to the checkpoint blockade armamentarium

(2019) Matthew D. Hellmann et al.   NATURE MEDICINE

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

(2019) Jih-Hsiang Lee et al.   INVESTIGATIONAL NEW DRUGS

Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors

(2019) Miro K Viitala et al.   CLINICAL CANCER RESEARCH

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages

(2019) C A Gomez-Roca et al.   ANNALS OF ONCOLOGY

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

(2019) Karen A. Autio et al.   JOURNAL OF CLINICAL ONCOLOGY

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

(2019) Philippe Alexandre Cassier et al.   JOURNAL OF CLINICAL ONCOLOGY

Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.

(2019) Ahmad Awada et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.

(2019) Jasgit C. Sachdev et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort.

(2019) Osama E. Rahma et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.

(2019) Malaka Ameratunga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

(2019) Nataliya Volodymyrivna Uboha et al.   JOURNAL OF CLINICAL ONCOLOGY

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

(2019) John D. Powderly et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.

(2019) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

(2019) Kyriakos P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages

(2019) Pedro Cabrales   Translational Oncology

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

(2019) R. Advani et al.   HEMATOLOGICAL ONCOLOGY

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

(2019) Marcus Noel et al.   INVESTIGATIONAL NEW DRUGS

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

(2019) Pengfei Zhao et al.   Journal of Hematology & Oncology

Immune Checkpoint Inhibitor Toxicities

(2019) Julian A. Marin-Acevedo et al.   MAYO CLINIC PROCEEDINGS

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

(2019) Mónica Pascual-García et al.   Nature Communications

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

T Cell Dysfunction in Cancer Immunity and Immunotherapy

(2019) Anliang Xia et al.   Frontiers in Immunology

Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial

(2019) Ali A. Mokdad et al.   Targeted Oncology

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

(2019) Marijo Bilusic et al.   Journal for ImmunoTherapy of Cancer

1109OA phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

(2019) R Galot et al.   ANNALS OF ONCOLOGY

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

(2019) Chenjing Zhu et al.   Molecular Cancer

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

(2019) Lawrence P. Andrews et al.   NATURE IMMUNOLOGY

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis

(2019) Martha Gschwandtner et al.   Frontiers in Immunology

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers

(2018) Tao Jiang et al.   BMC CANCER

Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression

(2018) Balsam Rizeq et al.   CANCER SCIENCE

CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy

(2018) Yoji Murata et al.   CANCER SCIENCE

CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises

(2018) Bing Tong et al.   Future Oncology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

(2018) Melissa A. Eastgate et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

(2018) Nehal J. Lakhani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

(2018) Julie Marie Collins et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

(2018) David S. Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

(2018) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

(2018) Aitana Calvo et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

(2018) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL

Conserved and variable natural killer cell receptors: diverse approaches to viral infections

(2018) Leidy Y. Bastidas-Legarda et al.   IMMUNOLOGY

TIM-3, a promising target for cancer immunotherapy

(2018) Yayi He et al.   OncoTargets and Therapy

On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies

(2018) Andreea Calinescu et al.   Journal of Immunology Research

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

IL-1 and IL-1 regulatory pathways in cancer progression and therapy

(2017) Alberto Mantovani et al.   IMMUNOLOGICAL REVIEWS

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

Potential targeting of B7-H4 for the treatment of cancer

(2017) Joseph R. Podojil et al.   IMMUNOLOGICAL REVIEWS

The family of the interleukin-1 receptors

(2017) Diana Boraschi et al.   IMMUNOLOGICAL REVIEWS

Overview of the IL-1 family in innate inflammation and acquired immunity

(2017) Charles A. Dinarello   IMMUNOLOGICAL REVIEWS

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

(2017) Wenwen Du et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

M1 Means Kill; M2 Means Heal

(2017) Klaus Ley   JOURNAL OF IMMUNOLOGY

Significance of CD47 expression in gastric cancer

(2017) Tomoya Sudo et al.   Oncology Letters

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy

(2017) Floris Dammeijer et al.   Cancer Immunology Research

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

(2017) Michael A. Cannarile et al.   Journal for ImmunoTherapy of Cancer

Targeting myeloid cells in the tumor sustaining microenvironment

(2017) Jonathan Schupp et al.   CELLULAR IMMUNOLOGY

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity

(2016) Pierre-Louis Loyher et al.   CANCER RESEARCH

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

(2016) E. Picarda et al.   CLINICAL CANCER RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of CD112R as a novel checkpoint for human T cells

(2016) Yuwen Zhu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer

(2016) Sukhbir Kaur et al.   Oncotarget

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

(2016) Xinqi Wu et al.   Cancer Immunology Research

Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation

(2015) Alexander Scholz et al.   Annals of the New York Academy of Sciences

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

(2015) Zhenyu Xiao et al.   CANCER LETTERS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

(2015) Dass S. Vinay et al.   SEMINARS IN CANCER BIOLOGY

Macrophages and cancer: from mechanisms to therapeutic implications

(2015) Renato Ostuni et al.   TRENDS IN IMMUNOLOGY

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies

(2015) E. E. Evans et al.   Cancer Immunology Research

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

(2015) Robert D. Leone et al.   Computational and Structural Biotechnology Journal

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

The Interleukin-1 Family: Back to the Future

(2013) Cecilia Garlanda et al.   IMMUNITY

Biology of the TAM Receptors

(2013) G. Lemke   Cold Spring Harbor Perspectives in Biology

Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation

(2013) Y. Yin et al.   Cancer Immunology Research

Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1

(2012) Jamie L. McClellan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Angiopoietin-2 promotes myeloid cell infiltration in a  2-integrin-dependent manner

(2011) A. Scholz et al.   BLOOD

Melanoma drug wins US approval

(2011) Heidi Ledford   NATURE

CCL2 Blockade Augments Cancer Immunotherapy

(2009) Z. G. Fridlender et al.   CANCER RESEARCH

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE